CN110302383A - The purposes of TRIM11 gene and albumen target spot and inhibitor in breast cancer - Google Patents
The purposes of TRIM11 gene and albumen target spot and inhibitor in breast cancer Download PDFInfo
- Publication number
- CN110302383A CN110302383A CN201910686481.9A CN201910686481A CN110302383A CN 110302383 A CN110302383 A CN 110302383A CN 201910686481 A CN201910686481 A CN 201910686481A CN 110302383 A CN110302383 A CN 110302383A
- Authority
- CN
- China
- Prior art keywords
- trim11
- drug
- albumen
- gene
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the purposes of TRIM11 gene and albumen target spot and inhibitor in breast cancer, the purposes using TRIM11 gene or TRIM11 albumen as drug target in the drug for screening and/or preparing prevention and/or treatment breast cancer is specifically disclosed；Purposes of the inhibitor of TRIM11 gene or TRIM11 albumen in the drug that preparation treats or prevents breast cancer；And the purposes of anti-tumor drug drug of sensibility in mammary gland cancerous precaution and/or treatment is improved in screening using TRIM11 gene or TRIM11 albumen as drug target；The composition of the inhibitor and anti-tumor drug of TRIM11 gene or TRIM11 albumen, the purposes in the drug that preparation treats or prevents breast cancer.
Description
Technical field
The invention belongs to pharmaceutical fields, and in particular to targeting TRIM11 protein screening treat or prevent breast cancer drug or
The method for improving drug effect.
Background technique
Malignant tumour wide variety, property type is different, the tissue that involves is different with organ, stadium is different, to various
The reaction for the treatment of is also different, therefore most of patient needs to carry out complex treatment.It is mainly comprehensive for oncotherapy at present to use
The means such as operation, chemotherapy, radiotherapy, immunization therapy, traditional Chinese medical herbal treatment, interventional therapy, micro-wave therapeutic, to greatly mention
High curative rate, and improve the quality of life of patient.Current more and more new antitumor drugs are applied to clinic, this is for promoting cancer
Life cycle of the patient and quality of life for improving them is particularly important；However in many cases, due to drug resistance of tumor
The generation of (Cancer drug resistance), so that the anticarcinogen that initial stage curative effect is fabulous, no longer plays effect in the later period
Fruit, and then lead to the recurrence and repeatedly of cancer.Although current tumor therapeuticing method makes rapid progress, chemotherapy is still tumor patient pole
For effective and real selection, and failure of about 90% chemotherapy in tumor-infiltrated and transfer is all related with drug resistance of tumor；
Therefore, drug resistance of tumor is all a huge and serious problem for entire therapeutic field of tumor.The generation of drug resistance of tumor
Process is very complicated, and the mechanism of drug resistance of tumor cell is also varied, such as makes drug inactivation, the generation of multidrug resistance, cell dead
It dies/inhibition of apoptosis, changes drug-metabolic pathway or drug target, changes epigenetic, enhancing DNA damage and target gene amplification
Deng.So finding and illustrating new tumor cell drug resistance mechanism, for new shot design drug and then tumor drug resistance is overcome
Property, this is of great significance for more effective oncotherapy.
Bortezomib (Bortezomib/BTZ, PS-341, Velcade) passes through the reversible inhibition albumen of boric acid dipeptides
Enzyme body activity is first proteasome inhibitor for being applied to clinical treatment by U.S. Food and Drug Administration (FDA),
It is mainly used for the treatment of Huppert's disease (Multiple myeloma, MM) and lymphoma mantle cell.
So far, bortezomib in treatment of solid tumors application it is more limited, such as treat breast cancer, lung cancer with
And the trial of prostate cancer, fail to obtain good curative effect, wherein critically important one the reason is that be likely that there are it is specific or
For the drug resistance of bortezomib in all solid tumors, and by finding bortezomib resistance mechanism completely new in tumour, then
Antineoplaston based on bortezomib is of great significance.
Breast cancer is a kind of common malignant tumour, is global women because cancer leads to dead first cause.At present
Know that bortezomib is not high to solid tumor breast cancer curative effect, reason is that breast cancer cell has centainly bortezomib
Drug resistance, but we are unclear for resistance mechanism involved in it.
It is reported that TRIM11 is a kind of oncogene, it is found in various types of cancers and works recently, including ovary
Cancer and lung cancer and breast cancer.
Bortezomib is mainly used for the treatment of Huppert's disease and lymphoma mantle cell at present, not to solid tumor curative effect
Height, use scope are extremely limited.In view of above, the relationship between TRIM11 and bortezomib and breast cancer is understood fully, for finding
The resistance mechanism of bortezomib can provide thinking, be more widely applied bortezomib in the treatment of tumour, rather than only office
It is limited to the treatment of lymthoma.
Inventor is considered because having limited to an application of bortezomib in solid tumor there are certain resistance mechanism.
Summary of the invention
In view of the above-mentioned problems, present invention finds TRIM11 albumen as action target spot, downward can promote cell to wither
It dies, increases the therapeutic effect of anti-tumor drug.And the reduction of therapeutic effect can be caused by being overexpressed TRIM11 then.
One aspect of the invention provide it is a kind of using TRIM11 gene or TRIM11 albumen as drug target screening with/
Or preparation prevents and/or treats the purposes in the drug of breast cancer.
Another aspect of the invention provide the inhibitor of TRIM11 gene or TRIM11 albumen a kind of in preparation treatment or
Prevent the purposes in the drug of breast cancer.
Another aspect of the invention, which is provided, to be improved using TRIM11 gene or TRIM11 albumen as drug target in screening
The purposes of anti-tumor drug drug of sensibility in mammary gland cancerous precaution and/or treatment.
Another aspect of the invention provides the inhibitor of TRIM11 gene or TRIM11 albumen and the group of anti-tumor drug
Close object.
Another aspect of the invention provides anti-tumor drug comprising active constituent and auxiliary material, the active constituent are
The inhibitor or TRIM11 gene of TRIM11 gene or TRIM11 albumen or the inhibitor and anti-tumor drug of TRIM11 albumen
Composition.
Another aspect of the invention provides the inhibitor of TRIM11 gene or TRIM11 albumen and the group of anti-tumor drug
Object is closed, the purposes in the drug that preparation treats or prevents breast cancer.
Another aspect of the invention provide the inhibitor of TRIM11 gene or TRIM11 albumen in the treatment of breast cancer or
The purposes for preventing middle raising anti-tumor drug sensibility or therapeutic effect.
In the inventive solutions, the anti-tumor drug is bortezomib.
Another aspect of the invention provides the breast cancer cell of TRIM11 Knockdown, it is preferable that breast cancer cell is
Breast cancer cell.
In the inventive solutions, the inhibitor of the TRIM11 albumen is TRIM11 protein antibodies or TRIM11 egg
White binding protein.
In the inventive solutions, the inhibitor of the TRIM11 gene is selected in TRIM11 gene specific
One of the microRNA of RNAi, TRIM11 gene specific or the inhibitor for inhibiting TRIM11 gene promoter or a variety of.
Beneficial effect
The present invention provides the novel targets of breast cancer treatment, while the sensitivity of other anti-tumor drugs can be improved in the target spot
Property and therapeutic effect, provide new direction for oncotherapy.
Detailed description of the invention
Fig. 1 is Western blot identification of the TRIM11 albumen in MCF7 cell line；Stablize and is overexpressed Flag-TRIM11
Or strike the breast cancer MCF7 Establishment of Cell Line of low TRIM11.(A) stablized using retroviral construct and be overexpressed control group
(Vector) or the MCF7 cell line of Flag-TRIM11, the protein level of immunoblotting assay Flag-TRIM11.Wherein
Tubulin is internal reference albumen.(B) stablized using adenovirus construction and strike low control (shNC) or TRIM11 (shTRIM11-1/2)
MCF7 cell line, the protein level of immunoblotting assay TRIM11.Wherein GAPDH is internal reference albumen.
Fig. 2 is the apoptosis situation of the MCF7 cell under bortezomib (BTZ) treatment conditions；Analyze TRIM11 expression quantity with
Bortezomib kills the effect of tumour, strikes MCF7 Apoptosis under low, the these types of processing of bortezomib with use in conjunction TRIM11
Situation.(A) in MCF7 cell stablize be overexpressed control (vector) or TRIM11, various concentration BTZ (+, 25nM；++,
It 50nM) handles 16 hours, flow cytometer showed Apoptosis ratio.(B) stablized in MCF7 cell strike low control (shNC) or
TRIM11 (shTRIM11-1, -2), BTZ drug (25nM) are handled 16 hours, flow cytometer showed Apoptosis ratio.The data of presentation
Represent average value ± SEM (n=3).*,P<0.05,***,P<0.001.
Fig. 3 is the measurement of nude mouse tumor growth；The measurement of nude mouse tumor growth.Wherein Fig. 3-A is cellular control unit injection
After mouse through PBS or BTZ (500ug/kg) processing after mouse tumor volume；Fig. 3-B is then the MCF7 of experimental group Flag-TRIM11
After cell infusion mouse through PBS or BTZ (500ug/kg) processing after mouse tumor volume.The data of presentation represent average value ±
SEM (n=4).*, P < 0.05, n.s., no significant difference.
Fig. 4 is the measurement of nude mouse tumor weight；The measurement of nude mouse tumor weight.Fig. 4-A is swollen to be taken after execution mouse
Tumor tissue；Fig. 4-B is then the comparison of its each group tumor weight after mouse tumor tissue weighs.The data of presentation represent average value
± SEM (n=4).*,P<0.05；**,P<0.01；N.s., no significant difference.
Specific embodiment
The tumor cell line for being overexpressed or striking low TRIM 11 is stablized in building first, is then handled and was stablized with bortezomib
The tumor cell line for expressing or striking low TRIM 11 sees that the expression quantity of TRIM11 is replaced with boron by flow cytometer detection Apoptosis situation
The effect that rice kills tumour is helped, mouse subcutaneous tumors model is then set up, and handled with bortezomib, monitors the growth of mouse tumor
Situation finally puts to death mouse, and tumor tissue is taken to weigh.
The MCF7 cell line for being overexpressed or striking low TRIM 11 is stablized in the preparation of embodiment 1
The tumor cell line stablized and be overexpressed or strike low TRIM 11 is constructed using slow virus, is then screened with puromycin
Surely turned cell line, gained is stablized to the MCF7 cell line collection a part progress western for being overexpressed or striking low TRIM 11
Blot detection, the results showed that TRIM11 is overexpressed/strikes low, so far arrive and stablizes overexpression or strike the MCF7 cell line of low TRIM 11.
One, the MCF7 cell line stablized and be overexpressed TRIM11 is established
1. packing slow virus
(1) 293T bed board, 10cm ware, 2-4*10^6cells/dish, 6ml DMEM+10%FBS culture medium are close to cell
Degree is transfected up to 60%-80%
(2) three plasmid systems transfect cell: pCMV-DR8.91:pCMV-VSVG:
TRPE-GFP-mCherry/TRPE-TRIM11-mCherry=9:1:10
A. 1. 25ul Lipo3000+700ulOptiMEM, 2. 15ul P3000+700ulOptiMEM+6ug plasmid,
B. will 1.+2. mix, RT10-15min, 1.4ml/dish.
C.4-6h liquid is changed, (20-30%) containing serum is free of dual anti-
D. viral supernatants is collected in culture 48-72h (37 DEG C, 5%CO2) afterwards
(3) viral supernatants are collected
A. by viral supernatants 3000r, 4 degree of centrifugation 10min.
B.0.22um filter filter virus supernatant
2. virus infection MCF7 tumor cell line
A. collect virus the previous day by MCF7 cell dissociation spread 6 orifice plates, 1-2*10^5cells/dish,
B.1ml viral supernatants+1ml (DMEM+10%FBS) culture medium+polybrene (8ug/ml) infects
3.Western blot detection
Cell progress Western blot detection is collected after infecting 24-48h
The result shows that TRIM11 is overexpressed (Figure 1A) in MCF7 cell
Two, the MCF7 cell line stablized and strike low TRIM11 is established
1. packing slow virus
(1) 293T bed board, 10cm ware, 2-4*10^6cells/dish, 6ml DMEM+10%FBS culture medium are close to cell
Degree is transfected up to 60%-80%
(2) three plasmid systems transfection cell: pCMV-DR8.91:pCMV-VSVG:pLKO.1 (pLKO.1-shTRIM11,
PLKO.1-shTRIM11)=9:1:10
A. 1. 25ul Lipo3000+700ulOptiMEM, 2. 15ul P3000+700ulOptiMEM+6ug plasmid,
B. will 1.+2. mix, RT10-15min, 1.4ml/dish.
C.4-6h liquid is changed, (20-30%) containing serum is free of dual anti-
D. viral supernatants is collected in culture 48-72h (37 DEG C, 5%CO2) afterwards
(3) viral supernatants are collected
A. by viral supernatants 3000r, 4 degree of centrifugation 10min.
B.0.22um filter filter virus supernatant
2. virus infection MCF7 tumor cell line
A. collect virus the previous day by MCF7 cell dissociation spread 6 orifice plates, 1-2*10^5cells/dish,
B.1ml viral supernatants+1ml (DMEM+10%FBS) culture medium+polybrene (8ug/ml) infects
C.24 it after hour, changes liquid and 1ug/mlpuromycin is added to screen 3-5 days
3.Western blot detection
It collects cell and carries out Western blot detection
The result shows that TRIM11 is struck low (Figure 1B) in MCF7 cell
Experimental result is referring to attached drawing 1.
The antitumor cell of 2 bortezomib energy antagonism BTZ of embodiment is tested
The MCF7 cell line stablized and be overexpressed or strike low TRIM 11 is handled with bortezomib (BTZ), collects cell apoptosis
Kit handles cell, and passes through flow cytometer detection Apoptosis situation, the results showed that after bortezomib (25nM, 50nM) processing,
MCF7-TRIM11 experimental group Apoptosis is low compared with control group；When no bortezomib is handled, TRIM11 is struck low group cell
Apoptosis is higher than control group；After bortezomib processing, it is higher than control group that TRIM11 is struck low group Apoptosis.Illustrate boron
The anti-tumor effect of Bortezomib energy antagonism BTZ.
1. in MCF7 cell stablize be overexpressed control (vector) or TRIM11, various concentration BTZ drug (+, 25nM；+
+, 50nM) processing 16 hours, flow cytometer showed Apoptosis ratio.
(1) MCF7-Vector that will be built, MCF7-TRIM11 cell line digestion paving 6 orifice plates, 2-5*10^5cells/
well
(2) add various concentration BTZ drug (25nM, 50nM) processing after 16-18h
(3) after 16h, digestion is collected cell and is operated by apoptosis kit specification
(4) flow cytometer detection
Low control (shNC) or TRIM11 (shTRIM11-1, -2), BTZ drug are struck 2. stablizing in MCF7 cell
(25nM) is handled 16 hours, flow cytometer showed Apoptosis ratio.
(1) MCF7-shNC that will be built, MCF7-TRIM11-1, MCF7-TRIM11-2 cell line digestion paving 6 orifice plates,
2-5*10^5cells/well
(2) add various concentration BTZ drug (25nM) processing after 16-18h
(3) after 16h, digestion is collected cell and is operated by apoptosis kit specification
(4) flow cytometer detection
Experimental result is referring to attached drawing 2
The antitumor zoopery of 3 bortezomib energy antagonism BTZ of embodiment
Mouse subcutaneous tumors model is established, with BTZ drug-treated, the growing state of mouse tumor is monitored, finally puts to death mouse,
Tumor tissue is taken to weigh.
1.BALb/c nude mouse subcutaneous injection breast cancer cell: control:MCF7-Vector cell；
Experiment:MCF7-Trim11 cell；
(1) prepare cell
Injecting cell number is 1 × 106A/mouse
A. plus the good cell of pancreatin digest amplification,
B. the same cells digested are merged, is gone in 15mL centrifuge tube, 1000rpm is centrifuged 2min, removes supernatant
C. every pipe adds 1~2mL, 1 × PBS to be resuspended, and counts after dispelling
D. according to count results, cell is assigned in tube, each tube points 1 × 106A cell
E. centrifugation remove supernatant, add 75 μ L serum-frees be resuspended DMEM, then plus 25 μ L Matrigel, mix, can be used to infuse
It penetrates.
Note: Matrigel needs -20 DEG C of preservations, needs to take out being put into 4 DEG C of changes before use in advance, can change overnight, cell suspension:
Matrigel=3:1.
(2) right side of mice is subcutaneously injected close to underarm region
(3) after injecting, the tumorous size of survey in 2-3 days
(4) tumour growth starts administration (this time starting to be administered at the 10th day) afterwards to a certain extent, is both needed to daily after administration
Survey mouse tumor volume
2.BALb/c nude mouse administration grouping (4/group): a.control+PBS；b.control+BTZ(500ug/
kg)；c.F-Trim11+PBS；d.F-Trim11+BTZ(500ug/kg)；Mode: intraperitoneal injection；Period: three times a week, administration
1-2 weeks；
3. Indexs measure:
(1) subcutaneous transplantation knurl product calculates: calculating (tumor diameter maximum is no more than 2cm) (Fig. 3) by π/6 × L × W^2；
(2) tumour weighing (Fig. 4)
The result shows that mouse tumor volume and weight has significance difference compared with only injecting PBS after control group mice administration
Not, all decline；And without significant difference compared with only injecting PBS after experimental mice administration.
Experimental result is shown in Fig. 3 and Fig. 4, Fig. 3 and Fig. 4 confirm that BTZ is used alone can inhibit tumour to a certain extent
Growth, but if TRIM be overexpressed if BTZ can be inhibited to the inhibiting effect of tumour.
Claims (10)
1. a kind of screening and/or preparing prevention and/or treatment cream using TRIM11 gene or TRIM11 albumen as drug target
Purposes in the drug of gland cancer.
2. a kind of purposes of the inhibitor of TRIM11 gene or TRIM11 albumen in the drug that preparation treats or prevents breast cancer.
3. using TRIM11 gene or TRIM11 albumen as drug target screening improve anti-tumor drug mammary gland cancerous precaution and/
Or treatment in sensibility drug purposes.
4. antineoplastic pharmaceutical compositions comprising active constituent and auxiliary material, the active constituent are TRIM11 gene or TRIM11
The composition of the inhibitor and anti-tumor drug of the inhibitor or TRIM11 gene or TRIM11 albumen of albumen.
The composition of the inhibitor and anti-tumor drug of 5.TRIM11 gene or TRIM11 albumen treats or prevents mammary gland in preparation
Purposes in the drug of cancer.
The inhibitor of 6.TRIM11 gene or TRIM11 albumen improves anti-tumor drug sensitivity in the treatment or prevention of breast cancer
The purposes of property or therapeutic effect.
7. composition according to claim 4 or purposes described in claim 5 or 6, wherein described is antitumor
Drug is bortezomib.
8. a kind of breast cancer cell of TRIM11 Knockdown, it is preferable that breast cancer cell is human breast cancer cell.
9. claim 2, purposes or anti-tumor drug as claimed in claim 4 described in any one of 5-6, wherein TRIM11
The inhibitor of albumen is the binding protein of TRIM11 protein antibodies or TRIM11 albumen.
10. claim 2, purposes or anti-tumor drug as claimed in claim 4 described in any one of 5-6, wherein described
The inhibitor of TRIM11 gene is selected in microRNA or the suppression of RNAi, TRIM11 gene specific of TRIM11 gene specific
One of inhibitor of TRIM11 gene promoter processed is a variety of.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910686481.9A CN110302383A (en) | 2019-07-29 | 2019-07-29 | The purposes of TRIM11 gene and albumen target spot and inhibitor in breast cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910686481.9A CN110302383A (en) | 2019-07-29 | 2019-07-29 | The purposes of TRIM11 gene and albumen target spot and inhibitor in breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110302383A true CN110302383A (en) | 2019-10-08 |
Family
ID=68081994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910686481.9A Pending CN110302383A (en) | 2019-07-29 | 2019-07-29 | The purposes of TRIM11 gene and albumen target spot and inhibitor in breast cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110302383A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113908280A (en) * | 2021-09-14 | 2022-01-11 | 深圳先进技术研究院 | Use of a combination of a TRIM11 inhibitor and metformin for the treatment of hepatocellular carcinoma |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009004484A2 (en) * | 2007-07-03 | 2009-01-08 | Board Of Regents, The University Of Texas System | Trim24 (tifla) as p53 modulator and cancer target |
| US20090029925A1 (en) * | 2007-07-23 | 2009-01-29 | Legacy Emanuel Hospital & Health Center | Interaction of bim with trim2, an e3 ubiquitin ligase |
| US20120087914A1 (en) * | 2008-03-27 | 2012-04-12 | Fred Hutchinson Cancer Research Center | Inhibition of trim62 activity reduces cancer cell proliferation |
| CN103865999A (en) * | 2012-12-18 | 2014-06-18 | 三星电子株式会社 | Composition and kit for diagnosing breast cancer, and method of diagnosing breast cancer using same |
| WO2017178509A1 (en) * | 2016-04-12 | 2017-10-19 | Xentech | Methods for predicting sensibility to treatment with parp inhibitors in cancerous patients |
| CN107723350A (en) * | 2016-08-12 | 2018-02-23 | 嘉兴允英医学检验有限公司 | A kind of hereditary breast cancer mutator high flux examination method |
| CN108271364A (en) * | 2015-05-29 | 2018-07-10 | 宾夕法尼亚大学理事会 | For the composition and method of the protein for false folding of degrading |
-
2019
- 2019-07-29 CN CN201910686481.9A patent/CN110302383A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009004484A2 (en) * | 2007-07-03 | 2009-01-08 | Board Of Regents, The University Of Texas System | Trim24 (tifla) as p53 modulator and cancer target |
| US20090029925A1 (en) * | 2007-07-23 | 2009-01-29 | Legacy Emanuel Hospital & Health Center | Interaction of bim with trim2, an e3 ubiquitin ligase |
| US20120087914A1 (en) * | 2008-03-27 | 2012-04-12 | Fred Hutchinson Cancer Research Center | Inhibition of trim62 activity reduces cancer cell proliferation |
| CN103865999A (en) * | 2012-12-18 | 2014-06-18 | 三星电子株式会社 | Composition and kit for diagnosing breast cancer, and method of diagnosing breast cancer using same |
| CN108271364A (en) * | 2015-05-29 | 2018-07-10 | 宾夕法尼亚大学理事会 | For the composition and method of the protein for false folding of degrading |
| WO2017178509A1 (en) * | 2016-04-12 | 2017-10-19 | Xentech | Methods for predicting sensibility to treatment with parp inhibitors in cancerous patients |
| CN107723350A (en) * | 2016-08-12 | 2018-02-23 | 嘉兴允英医学检验有限公司 | A kind of hereditary breast cancer mutator high flux examination method |
Non-Patent Citations (3)
| Title |
|---|
| LIANG CHEN ET AL: "TRIM11 activates the proteasome and promotes overall protein degradation by regulating USP14", 《NATURE COMMUNICATIONS》 * |
| LIANG CHEN ET AL: "TRIM11 cooperates with HSF1 to suppress the anti-tumor effect of proteotoxic stress drugs", 《CELL CYCLE》 * |
| 张洋 等: "TRIM11靶向调控 miR-24-3p促进乳腺癌细胞系MCF7增殖和侵袭", 《基础医学与临床》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113908280A (en) * | 2021-09-14 | 2022-01-11 | 深圳先进技术研究院 | Use of a combination of a TRIM11 inhibitor and metformin for the treatment of hepatocellular carcinoma |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3773877B1 (en) | Using alternating electric fields to increase cell membrane permeability | |
| Carvalho et al. | Radiotherapy and immune response: the systemic effects of a local treatment | |
| CN113388571A (en) | Liver targeted drug-loaded exosome and application and drug for treating liver diseases | |
| CN110302383A (en) | The purposes of TRIM11 gene and albumen target spot and inhibitor in breast cancer | |
| Lai et al. | Study on the mechanism of diosgenin targeting STAT3 to inhibit colon cancer proliferation and migration | |
| Chen et al. | Paeonol inhibits melanoma growth by targeting PD1 through upregulation of miR-139-5p | |
| Qi et al. | The inhibition of colorectal cancer growth by the natural product macrocarpal I | |
| Li et al. | Endostatin gene therapy enhances the efficacy of paclitaxel to suppress breast cancers and metastases in mice | |
| US20230270861A1 (en) | Inhibitors of the Artemin Pathway for Treatment of Cancer | |
| Xin et al. | Effect of VEGF-targeted antisense gene therapy on retinoblastoma cell line SO-RB50 in vitro and in vivo | |
| CN107823645B (en) | BET inhibitor combined with NF-kB inhibitor for treating colorectal cancer and pharmaceutical composition | |
| CN106075454A (en) | A kind of anti-tumor medicinal preparation combination | |
| CN105617401B (en) | Tumor radiation sensitization and radiation side effect weakening effects of miRNA, implementation method and application | |
| WO2022127788A1 (en) | Application of lenvatinib and aurora-a kinase inhibitor in preparing cancer-inhibiting drugs | |
| Gehre et al. | Simon Gehre1, 2, 3, Felix Meyer4, Azzaya Sengedorj1, 2, 3, Fridolin Grottker1, 2, 3, Clara M. Reichardt1, 2, 3, Jannik Alomo1, 2, 3, Kerstin Borgmann4, Benjamin Frey1, 2, 3, Rainer Fietkau2, 3, Michael Rückert1, 2, 3 and Udo S. Gaipl1, 2, 3 | |
| Jia-hui et al. | Lobaplatin Enhances Radioactive 125I Seed-Induced Apoptosis and Anti-Proliferative Effect in Non-Small Cell Lung Cancer by Suppressing the AKT/mTOR Pathway | |
| Gehre et al. | Clonogenicity-based radioresistance determines the expression of immune suppressive immune checkpoint molecules after hypofractionated irradiation of MDA-MB-231 triple-negative breast cancer cells | |
| Wang et al. | iRGD-modified exosomes encapsulate anti-miR-25-3p for targeted pancreatic cancer therapy | |
| CN116440275A (en) | Use of MOBAT1 in preparation of agent for treating cancer | |
| CN1283802C (en) | Recombinant adenovirus and its application in malignant tumor treatment | |
| CN106074574A (en) | A kind of medicine for treating the cancer of the esophagus and using method | |
| Kayabolen et al. | EXTH-10. COMBINATION OF EPIGENETIC ENZYME INHIBITORS, GSK-J4 AND BELINOSTAT, REVEALS HIGH EFFICACY IN IDH1 MUTANT GLIOMAS | |
| CN113633772A (en) | Medicine for treating liver cancer and verification model construction method and screening method thereof | |
| CN118059234A (en) | Application of anti-PD-1 monoclonal antibody combined mitoxantrone liposome in preparation of medicines for treating tumor heart complications | |
| CN117618574A (en) | Combination therapeutic compositions and combination therapeutic methods for tumor treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |